Welcome to ALTG

ALTG awarded $12 million in funding

The ALTG is pleased to announce over $12 million in funding has been successfully awarded to ALTG, NHMRC Clinical Trial Centre and the Australian Genomic Cancer Medicine Centre for the ASPiRATION project. In this ground-breaking precision medicine study, led by ALTG President A/Prof Nick Pavlakis and ALTG Scientific Advisory Committee Chair, Prof Ben Solomon, ASPiRATION will explore the benefit of routine comprehensive genomic profiling in 1000 newly-diagnosed metastatic, non-squamous, NSCLC patients in Australia. The enhanced genomic profiling will assist in personalising patient care by matching patients to targeted treatments as early as possible to improve patient outcomes.

New ALTG Study ILLUMINATE

ALTG Study, ILLUMINATE Study (ALTG 16/009) is now open to recruitment. This is a phase 2 trial of durvalumab and tremelimumab with chemotherapy in metastatic EGFR mutant non-squamous non-small cell lung cancer (NSCLC) following progression on epidermal growth factor receptor (EGFR) mutation Tyrosine Kinase Inhibitors (TKIs).

For Patients

Upcoming Events

Upcoming Events
  1. Australian Lung Cancer Conference 2020

    February 19 - February 21
  2. ALTG Open Scientific Advisory Committee Meeting

    February 19 @ 2:00 pm - 5:00 pm
  3. ALTG Open Management Advisory Committee Meeting

    February 20 @ 7:00 am - 8:00 am
  4. ALTG Strategic Planning Workshop

    February 21 @ 7:00 am - 9:00 am
  5. 6th ALTG Lung Cancer Preceptorship

    October 23 @ 8:00 am - October 24 @ 5:00 pm